Phase 3 Randomized Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) R-Chop Chemotherapy (R2-Chop) versus Placebo plus R-Chop Chemotherapy in Subjects with previously untreated Lymphoma